Neuralgia Treatments
Find Neuralgia Treatments
Generic Name
Pregabalin
Brand Names
Lyrica, Pregablin
FDA approval date: December 30, 2004
Form: Tablet, Capsule, Solution
What is Lyrica (Pregabalin)?
LYRICA is indicated for: Management of neuropathic pain associated with diabetic peripheral neuropathy Management of postherpetic neuralgia Adjunctive therapy for the treatment of partial-onset seizures in patients 1 month of age and older Management of fibromyalgia Management of neuropathic pain associated with spinal cord injury LYRICA is indicated for: Neuropathic pain associated with diabetic peripheral neuropathy Postherpetic neuralgia Adjunctive therapy for the treatment of partial-onset seizures in patients 1 month of age and older Fibromyalgia Neuropathic pain associated with spinal cord injury
Approved To Treat
Top Global Experts
Save this treatment for later
Not sure about your diagnosis?
Tired of the same old research?
Related Clinical Trials
Prospective Feasibility, Analgesic Effectiveness, and Safety Study of a Visual Analog Scale-Guided Multimodal Pain Algorithm After Posterior Rib Remodeling With Osteosynthesis
Summary: This prospective single-group study will evaluate a visual analog scale-guided multimodal analgesia algorithm during the first five days after posterior rib remodeling with osteosynthesis. Pain will be assessed at 6, 12, and 24 hours and every 12 hours thereafter through 120 hours. Treatment will be escalated or reduced according to prespecified pain tiers and safety rules. The primary outcome is ...
Sensory Phenotyping to Enhance Neuropathic Pain Drug Development (SPENDD): A Randomized, Double-blinded Cross-over Clinical Trial Aimed at Investigating Whether Bedside Quantitative Sensory Testing Can Predict Response to Analgesics.
Summary: The goal of this clinical trial is to determine whether quantitative sensory testing (QST) can be used to classify participants into pain sub-groups and predict who will respond best to certain pain treatments in participants with painful peripheral neuropathy. The analgesic effect is evaluated by measuring pain intensity and Patient Global Impression of Change (PGIC). This study is a 3-period cro...
Comparing the Efficacy and Safety of Pregabalin Monotherapy With Pregabalin Combined Other Neuromodulatory Drugs (Venlafaxine) in the Treatment of Fibromyalgia: A Multicenter Clinical Study
Summary: Fibromyalgia (FM) is a chronic pain syndrome characterized by widespread pain, fatigue, and emotional disorders. Its onset is related to factors such as central sensitization and imbalance of neurotransmitters. The current mainstream treatments include pregabalin, but the efficacy of pregabalin is limited, with only 25%-40% pain relief rate, and adverse reactions are common. Selective serotonin an...
Related Latest Advances
Brand Information
Lyrica (PREGABALIN)
1INDICATIONS AND USAGE
LYRICA is indicated for:
- Management of neuropathic pain associated with diabetic peripheral neuropathy
- Management of postherpetic neuralgia
- Adjunctive therapy for the treatment of partial-onset seizures in patients 1 month of age and older
- Management of fibromyalgia
- Management of neuropathic pain associated with spinal cord injury
2DOSAGE FORMS AND STRENGTHS
Capsules: 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg, and 300 mg
Oral Solution: 20 mg/mL
[see
3CONTRAINDICATIONS
LYRICA is contraindicated in patients with known hypersensitivity to pregabalin or any of its components. Angioedema and hypersensitivity reactions have occurred in patients receiving pregabalin therapy
4ADVERSE REACTIONS
The following serious adverse reactions are described elsewhere in the labeling:
- Angioedema
- Hypersensitivity
- Suicidal Behavior and Ideation
- Respiratory Depression
- Dizziness and Somnolence
- Increased Risk of Adverse Reactions with Abrupt or Rapid Discontinuation
- Peripheral Edema
- Weight Gain
- Tumorigenic Potential
- Ophthalmological Effects
- Creatine Kinase Elevations
- Decreased Platelet Count
- PR Interval Prolongation
4.1Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
In all controlled and uncontrolled trials across various patient populations during the premarketing development of LYRICA, more than 10,000 patients have received LYRICA. Approximately 5000 patients were treated for 6 months or more, over 3100 patients were treated for 1 year or longer, and over 1400 patients were treated for at least 2 years.
4.2Postmarketing Experience
The following adverse reactions have been identified during postapproval use of LYRICA. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Nervous System Disorders – Headache
Gastrointestinal Disorders – Nausea, Diarrhea
Reproductive System and Breast Disorders – Gynecomastia, Breast Enlargement
Skin and subcutaneous tissue disorders – Bullous pemphigoid
There are postmarketing reports of life-threatening or fatal respiratory depression in patients taking LYRICA with opioids or other CNS depressants, or in the setting of underlying respiratory impairment.
In addition, there are postmarketing reports of events related to reduced lower gastrointestinal tract function (e.g., intestinal obstruction, paralytic ileus, constipation) when LYRICA was co-administered with medications that have the potential to produce constipation, such as opioid analgesics.
5DRUG INTERACTIONS
Since LYRICA is predominantly excreted unchanged in the urine, undergoes negligible metabolism in humans (less than 2% of a dose recovered in urine as metabolites), and does not bind to plasma proteins, its pharmacokinetics are unlikely to be affected by other agents through metabolic interactions or protein binding displacement.
6DESCRIPTION
Pregabalin is described chemically as (
Pregabalin is a white to off-white, crystalline solid with a pK
LYRICA (pregabalin) Capsules are administered orally and are supplied as imprinted hard-shell capsules containing 25, 50, 75, 100, 150, 200, 225, and 300 mg of pregabalin, along with lactose monohydrate, cornstarch, and talc as inactive ingredients. The capsule shells contain gelatin and titanium dioxide. In addition, the orange capsule shells contain red iron oxide and the white capsule shells contain sodium lauryl sulfate and colloidal silicon dioxide. Colloidal silicon dioxide is a manufacturing aid that may or may not be present in the capsule shells. The imprinting ink contains shellac, black iron oxide, propylene glycol, and potassium hydroxide.
LYRICA (pregabalin) oral solution, 20 mg/mL, is administered orally and is supplied as a clear, colorless solution contained in a 16 fluid ounce white HDPE bottle with a polyethylene-lined closure. The oral solution contains 20 mg/mL of pregabalin, along with methylparaben, propylparaben, monobasic sodium phosphate anhydrous, dibasic sodium phosphate anhydrous, sucralose, artificial strawberry #11545 and purified water as inactive ingredients.
7PATIENT COUNSELING INFORMATION
Advise the patient to read the FDA-approved patient labeling (Medication Guide).
8PRINCIPAL DISPLAY PANEL - 25 mg Capsule Bottle Label
Pfizer
NDC 0071-1012-68
NDC 0071-1012-68
Lyrica®
(pregabalin)
capsules
(pregabalin)
capsules
CV
25 mg
ALWAYS DISPENSE WITH
MEDICATION GUIDE
MEDICATION GUIDE
90 Capsules
9PRINCIPAL DISPLAY PANEL - 50 mg Capsule Blister Pack
Lyrica
(pregabalin)
Capsule
(pregabalin)
Capsule
CV
50 mg
DIST BY PARKE-DAVIS
LOT 00000VX EXP XXX 00
10PRINCIPAL DISPLAY PANEL - 50 mg Capsule Blister Pack Carton
Pfizer
NDC 0071-1013-41
NDC 0071-1013-41
Lyrica®
(pregabalin) capsules
(pregabalin) capsules
CV
50 mg
ALWAYS DISPENSE WITH MEDICATION GUIDE
For in-institution use only
100 Capsules
11PRINCIPAL DISPLAY PANEL - 50 mg Capsule Bottle Label
Pfizer
NDC 0071-1013-68
NDC 0071-1013-68
Lyrica®
(pregabalin)
capsules
(pregabalin)
capsules
CV
50 mg
ALWAYS DISPENSE WITH
MEDICATION GUIDE
MEDICATION GUIDE
90 Capsules
12PRINCIPAL DISPLAY PANEL - 75 mg Capsule Blister Pack
Lyrica
(pregabalin)
Capsule
(pregabalin)
Capsule
CV
75 mg
DIST BY PARKE-DAVIS
LOT 00000VX EXP XXX 00
13PRINCIPAL DISPLAY PANEL - 75 mg Capsule Blister Pack Carton
Pfizer
NDC 0071-1014-41
NDC 0071-1014-41
Lyrica®
(pregabalin) capsules
(pregabalin) capsules
CV
75 mg
ALWAYS DISPENSE WITH MEDICATION GUIDE
For in-institution use only
100 Capsules
14PRINCIPAL DISPLAY PANEL - 75 mg Capsule Bottle Label
Pfizer
NDC 0071-1014-68
NDC 0071-1014-68
Lyrica®
(pregabalin)
capsules
(pregabalin)
capsules
CV
75 mg
ALWAYS DISPENSE WITH
MEDICATION GUIDE
MEDICATION GUIDE
90 Capsules
15PRINCIPAL DISPLAY PANEL - 100 mg Capsule Blister Pack
Lyrica
(pregabalin)
Capsule
(pregabalin)
Capsule
CV
100 mg
DIST BY PARKE-DAVIS
LOT 00000VX EXP XXX 00
16PRINCIPAL DISPLAY PANEL - 100 mg Capsule Blister Pack Carton
Pfizer
NDC 0071-1015-41
NDC 0071-1015-41
Lyrica®
(pregabalin) capsules
(pregabalin) capsules
CV
100 mg
ALWAYS DISPENSE WITH MEDICATION GUIDE
For in-institution use only
100 Capsules
17PRINCIPAL DISPLAY PANEL - 100 mg Capsule Bottle Label
Pfizer
NDC 0071-1015-68
NDC 0071-1015-68
Lyrica®
(pregabalin)
capsules
(pregabalin)
capsules
CV
100 mg
ALWAYS DISPENSE WITH
MEDICATION GUIDE
MEDICATION GUIDE
90 Capsules
18PRINCIPAL DISPLAY PANEL - 150 mg Capsule Blister Pack
Lyrica
(pregabalin)
Capsule
(pregabalin)
Capsule
CV
150 mg
DIST BY PARKE-DAVIS
LOT 00000VX EXP XXX 00
19PRINCIPAL DISPLAY PANEL - 150 mg Capsule Blister Pack Carton
Pfizer
NDC 0071-1016-41
NDC 0071-1016-41
Lyrica®
(pregabalin) capsules
(pregabalin) capsules
CV
150 mg
ALWAYS DISPENSE WITH MEDICATION GUIDE
For in-institution use only
100 Capsules
20PRINCIPAL DISPLAY PANEL - 150 mg Capsule Bottle Label
Pfizer
NDC 0071-1016-68
NDC 0071-1016-68
Lyrica®
(pregabalin)
capsules
(pregabalin)
capsules
CV
150 mg
ALWAYS DISPENSE WITH
MEDICATION GUIDE
MEDICATION GUIDE
- 90 Capsules
21PRINCIPAL DISPLAY PANEL - 200 mg Capsule Bottle Label
Pfizer
NDC 0071-1017-68
NDC 0071-1017-68
Lyrica®
(pregabalin)
capsules
(pregabalin)
capsules
CV
200 mg
ALWAYS DISPENSE WITH
MEDICATION GUIDE
MEDICATION GUIDE
90 Capsules
22PRINCIPAL DISPLAY PANEL - 225 mg Capsule Bottle Label
Pfizer
NDC 0071-1019-68
NDC 0071-1019-68
Lyrica®
(pregabalin)
capsules
(pregabalin)
capsules
CV
225 mg
ALWAYS DISPENSE WITH
MEDICATION GUIDE
MEDICATION GUIDE
- 90 Capsules
23PRINCIPAL DISPLAY PANEL - 300 mg Capsule Bottle Label
Pfizer
NDC 0071-1018-68
NDC 0071-1018-68
Lyrica®
(pregabalin)
capsules
(pregabalin)
capsules
CV
300 mg
ALWAYS DISPENSE WITH
MEDICATION GUIDE
MEDICATION GUIDE
- 90 Capsules
24PRINCIPAL DISPLAY PANEL - 20 mg Bottle Label
Pfizer
NDC 0071-1020-01
Lyrica®
(pregabalin)
(pregabalin)
CV
20 mg per mL
oral solution
ALWAYS DISPENSE WITH MEDICATION GUIDE
FOR ORAL USE ONLY
16 fl oz (473 mL)
25PRINCIPAL DISPLAY PANEL - 20 mg Bottle Carton
Pfizer
NDC 0071-1020-01
Lyrica
CV
20 mg per mL
oral solution
ALWAYS DISPENSE WITH MEDICATION GUIDE
FOR ORAL USE ONLY
16 fl oz (473 mL)
